eISSN: 2449-9315
ISSN: 1234-8279
Pharmacotherapy in Psychiatry and Neurology/Farmakoterapia w Psychiatrii i Neurologii
Current issue Archive Manuscripts accepted About the journal Editorial board Reviewers Abstracting and indexing Subscription Contact Instructions for authors Ethical standards and procedures
vol. 38
Review article

Possibilities of therapeutic action of cannabinoids in neurodegenerative diseases

Anna A. Kaszyńska

University of Social Sciences and Humanities;
Uniwersytet Humanistycznospołeczny SWPS
Farmakoterapia w Psychiatrii i Neurologii 2022, 38 (1), 49–58
Online publish date: 2022/08/02
Article file
Get citation
JabRef, Mendeley
Papers, Reference Manager, RefWorks, Zotero
PlumX metrics:
1. Al-Chalabi A, Hardiman O. The epidemiology of ALS: a conspiracy of genes, environment, and time. Nat. Rev. Neurol. 2013; 9: 617-28.
2. Ashton CH, Moore PB, Gallagher P, Young AH. Cannabinoids in bipolar affective disorder: A review and discussion of their therapeutic potential. Journal of Psychopharmacology 2005; 19(3): 293-300.
3. Bartoli F, Riboldi I, Bachi B, Calabrese A, Moretti F, Crocamo C, Carrà G. Efficacy of Cannabidiol for Δ-9-Tetrahydrocannabinol-Induced Psychotic Symptoms, Schizophrenia, and Cannabis Use Disorders: A Narrative Review. Journal of Clinical Medicine 2021; 10(6), 1303.
4. Battistella G, Fornari E, Annoni J-M, Chtioui H, Dao K, Fabritius et al. Long-Term Effects of Cannabis on Brain Structure. Neuropsychopharmacology 2014; 39(9): 2041-2048.
5. Bilsland LG, Dick JRT, Pryce G, Petrosino S, Di Marzo V, Baker D et al. Increasing cannabinoid levels by pharmacological and genetic manipulation delay disease progression in SOD1 mice. FASEB J. 2006; 20: 1003-5.
6. Bińkowska A, Brzezicka A. Wpływ marihuany na aktywność elektryczną mózgu. Kosmos 2020; 69(1): 219-232.
7. Blázquez C, Chiarlone A, Sagredo O, Aguado T, Pazos MR, Resel E i wsp. Loss of striatal type 1 cannabinoid receptors is a key pathogenic factor in Huntington’s disease. Brain 2011; 134: 119-36.
8. Bolla K, Eldreth D, Matochik J, Cadet J. Neural substrates of faulty decision-making in abstinent marijuana users. NeuroImage 2005; 26(2): 480-492.
9. Borgan F, Beck K, Butler E, McCutcheon R, Veronese M, Vernon A, Howes OD. The effects of cannabinoid 1 receptor compounds on memory: A meta-analysis and systematic review across species. Psychopharmacology 2019; 236(11): 3257-3270.
10. Chye Y, Solowij N, Suo C, Batalla A, Cousijn J, Goudriaan AE. et al. Orbitofrontal and caudate volumes in cannabis users: A multi-site mega-analysis comparing dependent versus non-dependent users. Psychopharmacology 2017; 234(13): 1985-1995.
11. Costa B, Trovato AE, Comelli F, Giagnoni G, Colleoni M. The non-psychoactive cannabis constituent cannabidiol is an orally effective therapeutic agent in rat chronic inflammatory and neuropathic pain. European Journal of Pharmacology 2007; 556(1-3): 75-83.
12. Cousijn J, Wiers RW, Ridderinkhof KR, van den Brink W, Veltman DJ, Goudriaan AE. Grey matter alterations associated with cannabis use: Results of a VBM study in heavy cannabis users and healthy controls. NeuroImage 2012; 59(4): 3845-3851.
13. van den Elsen GAH, Ahmed AIA, Verkes R-J, Kramers C, Feuth T, Rosenberg PB et al. Tetrahydrocannabinol for neuropsychiatric symptoms in dementia: A randomized controlled trial, Neurology 2015; 84: 2338-2346.
14. van den Elsen GA, Tobben L, Ahmed AI, Verkes RJ, Kramers C, Marijnissen RM et al. Effects of tetrahydrocannabinol on balance and gait in patients with dementia: A randomised controlled crossover trial. J. Psychopharmacol. 2017; 31: 184-191.
15. Espejo-Porras F, García-Toscano L, Rodríguez-Cueto C, Santos-García I, de Lago E, Fernandez-Ruiz J. Targeting glial cannabinoid CB2 receptors to delay the progression of the pathological phenotype in TDP-43 (A315T) transgenic mice, a model of amyotrophic lateral sclerosis. Br. J. Pharmacol 2019; 176(10): 1585-1600.
16. van de Giessen E, Weinstein JJ, Cassidy CM, Haney M, Dong Z, Ghazzaoui R. et al. Deficits in striatal dopamine release in cannabis dependence. Molecular Psychiatry 2017; 22(1): 68-75.
17. Ferland J-MN, Hurd YL. Deconstructing the neurobiology of cannabis use disorder. Nature Neuroscience 2020; 23(5), 600-610.
18. Galán-Ganga M, Rodríguez-Cueto C, Merchán-Rubira J, Hernández F, Ávila J, Posada-Ayala M, Lanciego JL, Luengo E, Lopez MG, Rábano A, Fernández-Ruiz J, Lastres-Becker I. Cannabinoid receptor CB2 ablation protects against TAU induced neurodegeneration. Acta Neuropathologica Communications 2021; 9(1): 90.
19. Guttman Z, Moeller SJ, London ED. Neural underpinnings of maladaptive decision-making in addictions. Pharmacology Biochemistry and Behavior 2018; 164: 84-98.
20. Hardiman O, van den Berg LH, Kiernan MC. Clinical diagnosis and management of amyotrophic lateral sclerosis. Nat. Rev. Neurol. 2011; 7: 639-649.
21. He J-T, Li X-Y, Yang L, Zhao X. Astroglial connexins and cognition: Memory formation or deterioration? Bioscience Reports 2020; 40(1), BSR20193510.
22. Hill KP, Palastro MD, George TP. Therapeutic cannabis use in 2018: Where do we stand? The Lancet Psychiatry 2019; 6(2): 88-89.
23. Huzard D, Rappeneau V, Meijer OC, Touma C, Arango-Lievano, M., Garabedian, MJ., Jeanneteau, F. Experience and activity-dependent control of glucocorticoid receptors during the stress response in large-scale brain networks. Stress 2021; 24(2): 130-153.
24. Kim SH, Yang JW, Kim KH, Kim JU, Yook TH. A Review on Studies of Marijuana for Alzheimer’s Disease-Focusing on CBD, THC. Journal of Pharmacopuncture 2019; 22(4): 225-230.
25. Koenders L, Lorenzetti V, de Haan L, Suo C, Vingerhoets W, van den Brink W. et al. Longitudinal study of hippocampal volumes in heavy cannabis users. Journal of Psychopharmacology 2017; 31(8): 1027-1034.
26. Koob GF, Volkow ND. Neurobiology of addiction: A neurocircuitry analysis. The Lancet Psychiatry 2016; 3(8), 760-773.
27. de Lago E, FR-J, Moreno-Martet M, Espejo-Porras F. Endocannabinoids and amyotrophic lateral sclerosis, in: Fattore L. (Ed.), Cannabinoids in Neurologic and Mental Disease, Elsevier 2015: 99-124.
28. Laprairie RB, Warford JR, S. Hutchings S, Robertson GS, Kelly MEM, Denovan-Wright EM. The cytokine and endocannabinoid systems are co-regulated by NF-κB p65/RelA in cell culture and transgenic mouse models of Huntington’s disease and in striatal tissue from Huntington’s disease patients. J. Neuroimmunol. 2014; 267: 61-72.
29. Leroy C, Karila L, Martinot J-L, Lukasiewicz M, Duchesnay E, Comtat C et al. Striatal and extrastriatal dopamine transporter in cannabis and tobacco addiction: A high-resolution PET study: DAT availability in addictions. Addiction Biology 2012; 17(6): 981-990.
30. Mievis S, Blum D, Ledent C. Worsening of Huntington disease phenotype in CB1 receptor knockout mice. Neurobiol. Dis. 2011; 42: 524-9.
31. Millington C, Sonego S, Karunaweera N, Rangel A, Aldrich-Wright JR, Campbell IL et al. Chronic Neuroinflammation in Alzheimer’s Disease: New Perspectives on Animal Models and Promising Candidate Drugs. BioMed Research International 2014; 2014: 1-10.
32. Morgan CJ, Freeman TP, Schafer GL, Curran HV. Cannabidiol Attenuates the Appetitive Effects of Δ9-Tetrahydrocannabinol in Humans Smoking Their Chosen Cannabis. Neuropsychopharmacology 2010; 35(9): 1879-1885.
33. Muetzel RL, Marjańska M, Collins PF, Becker MP, Valabrègue R, Auerbach EJ et al. In vivo 1H magnetic resonance spectroscopy in young-adult daily marijuana users. NeuroImage: Clinical 2013; 2: 581-589.
34. O’Donnell BF, Skosnik PD, Hetrick WP, Fridberg DJ. Decision Making and Impulsivity in Young Adult Cannabis Users. Frontiers in Psychology 2021; 12.
35. Pasquarelli N, Engelskirchen M, Hanselmann J, Endres S, Porazik C, Bayer H., et al. Evaluation of monoacylglycerol lipase as a therapeutic target in a transgenic mouse model of ALS., Neuropharmacology 2017; 124: 157-169.
36. Patricio F, Morales-Andrade AA, Patricio-Martínez A, Limón ID. Cannabidiol as a Therapeutic Target: Evidence of its Neuroprotective and Neuromodulatory Function in Parkinson’s Disease. Frontiers in Pharmacology 2020; 11.
37. Pietropaolo S, Bellocchio L, Ruiz-Calvo A, Cabanas M, Du, M. Guzmán M et al. Chronic cannabinoid receptor stimulation selectively prevents motor impairments in a mouse model of Huntington’s disease. Neuropharmacology 2015; 89: 368-74.
38. Pintor A, Tebano MT, Martire A, Grieco R, Galluzzo M, Scattoni ML et al. The cannabinoid receptor agonist WIN 55,212-2 attenuates the effects induced by quinolinic acid in the rat striatum. Neuropharmacology 2006; 51: 1004-12.
39. Prescot AP, Locatelli AE, Renshaw PF, Yurgelun-Todd DA. Neurochemical alterations in adolescent chronic marijuana smokers: A proton MRS study. NeuroImage 2011; 57(1): 69-75.
40. Ramírez BG, Blázquez C, Gómez del Pulgar T, Guzmán M, de Ceballos ML. Prevention of Alzheimer’s disease pathology by cannabinoids: neuroprotection mediated by blockade of microglial activation. J. Neurosci. 2005; 25: 1904-13.
41. Renton AE, Majounie E, Waite A, Simón-Sánchez J, Rollinson S, Gibbs JR et al. A Hexanucleotide Repeat Expansion in C9ORF72 Is the Cause of Chromosome 9p21-Linked ALS- FTD. Neuron. 2011; 72: 257-268.
42. Ross CA, Kronenbuerger M, Duan W, Margolis RL. Mechanisms underlying neurodegeneration in Huntington disease: applications to novel disease-modifying therapies. Handb. Clin. Neurol. 2017; 144: 15-28.
43. Rüb U, Seidel K, Heinsen H, Vonsattel JP, den Dunnen WF, Korf HW, Huntington’s disease (HD): the neuropathology of a multisystem neurodegenerative disorder of the human brain. Brain Pathol. 2016; 26: 726-740.
44. Saft C, Djamshidian A, Heim B, Seppi K. Cannabinoids for Treatment of Dystonia in Huntington’s Disease. 7.
45. Sagar KA, Gruber SA. Interactions between recreational cannabis use and cognitive function: Lessons from functional magnetic resonance imaging. Annals of the New York Academy of Sciences 2019; 1451(1): 42-70.
46. Sagredo O, Pazos MR, Valdeolivas S, Fernandez-Ruiz J. Cannabinoids: novel medicines for the treatment of Huntington’s disease. Recent Pat. CNS Drug Discov 2012; 7 41-8.
47. Sampaio C, Borowsky B, Reilmann R. Clinical trials in Huntington’s disease: Interventions in early clinical development and newer methodological approaches. Mov. Disord. 2014; 29: 1419-28.
48. Schuster RM, Hoeppner SS, Evins AE, Gilman JM. Early onset marijuana use is associated with learning inefficiencies. Neuropsychology 2016; 30(4): 405-415.
49. Sharman MJ, Verdile G, Kirubakaran S, Parenti C, Singh A, Watt G, Karl T, Chang D, Li CG, Münch G. Targeting Inflammatory Pathways in Alzheimer’s Disease: A Focus on Natural Products and Phytomedicines. CNS Drugs 2019; 33(5): 457-480.
50. Solowij N, Jones KA, Rozman ME, Davis SM, Ciarrochi J, Heaven PCL, Lubman DI, Yücel M. Verbal learning and memory in adolescent cannabis users, alcohol users and non-users. Psychopharmacology 2011; 216(1): 131-144.
51. Stella N. Genetic rescue of CB1 receptors on medium spiny neurons prevents loss of excitatory striatal synapses but not motor impairment in HD mice. Neurobiol. Dis. 2014; 71: 140-50.
52. Volkow ND, Baler RD, Compton WM, Weiss SRB. Adverse Health Effects of Marijuana Use. New England Journal of Medicine 2014; 370(23): 2219-2227.
53. Witting A, Weydt P, Hong S, Kliot M, Moller T, Stella N. Endocannabinoids accumulate in spinal cord of SOD1 G93A transgenic mice. J. Neurochem. 2004; 89: 1555-7.
54. Zuccato C, Cattaneo E. Huntington’s disease. Handb. Exp. Pharmacol. 2014; 220: 357-409.
55. Zuardi AW, Shirakawa I, Finkelfarb E, Karniol IG. Psychopharmacology C Springer-Verlag 1982; 76: 245-250.
Quick links
© 2023 Termedia Sp. z o.o. All rights reserved.
Developed by Bentus.